|Bid||218.62 x 1400|
|Ask||219.55 x 1200|
|Day's Range||215.05 - 219.05|
|52 Week Range||154.52 - 247.64|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||41.92|
|Earnings Date||Jul 21, 2020 - Jul 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||242.68|
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Edwards Lifesciences Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation (TR).
Artisan Mid Cap Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -11.55% for the quarter (investor class), outperforming their benchmark, the Russell Midcap Index which returned -27.07% in the same quarter. You should check out Artisan Mid Cap Fund’s top 5 […]
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals.
On Wednesday, Edwards Lifesciences got a positive adjustment to its Relative Strength (RS) Rating, from 79 to 83. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. Edwards Lifesciences is working on a consolidation with a 247.74 entry.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to participate in two upcoming investor conferences.
Edwards Lifesciences (NYSE: EW) shares rose 15.3% in April, according to data provided by S&P Global Market Intelligence. Edwards Lifesciences, like many other companies across industries, fell in March as the coronavirus outbreak deepened in the U.S. With stay-at-home orders issued across the country, investors worried about the impact of the health crisis on businesses' earnings. Transcatheter aortic valve replacement (TAVR) with the Sapien 3 continued to show favorable results for these patients compared with surgery.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
Wedgewood Partners, a St. Louis, Missouri-based investment management firm, released its Q1 2020 Investor letter – a copy of which is available for download here. Wedgewood Partners returned -16.30% for the first quarter. Meanwhile, the benchmark Russell 1000 Growth Index and the S&P 500 Index lost 14.10% and 19.60%, respectively. In the said letter, Wedgewood Partners […]
Today's 4 Stock Ideas: * Boeing (BA) \- An earnings play. The company will report quarterly results Wednesday morning before the market open. * F5 Networks (FFIV) \- A play on strong guidance. With the company's Q2 earnings report issued Monday afternoon, F5 said it expects Q3 EPS of $1.91-$2.13 vs the analyst consensus estimate of $1.84. Sales are expected to be between $555 million and $585 million vs the analyst estimate of $546.9 million. * Edwards Lifesciences (EW) \- A play on patient monitoring. The company said its HemoSphere platform received expanded use indication from Health Canada related to coronavirus patients. * ATIF Holdings (ATIF) \- A play on 5G and AI info distribution. The company on Monday outlined a plan for its platform to integrate data of urban cities.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Fri., Apr. 24, 2020: GILD, DKNG, FFIV, ADC, SGMS * Benzinga Pro's Top 5 Stocks To Watch For Thurs., Mar. 12, 2020: BA, APT, UBER, APRN, CHFS * Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 9, 2020: XOM, GLD, BA, TSLA, SPEX(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Health Canada approved an expanded indication for use of the HemoSphere advanced monitoring platform in the treatment of COVID-19 patients. This approval was granted following an interim order issued by Health Canada to address the pressing need for medical supplies used in the response to the COVID-19 pandemic. Hemodynamic monitoring refers to the measurement and tracking of different vital signs that help manage blood flow and oxygenation in critically ill patients, like those who are being treated for COVID-19.
Stocks were mixed early Friday after the passing of the coronavirus stimulus package. Chip giant Intel dove on earnings.
Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 17.05% and 7.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences called for a 2020 slowdown due to the coronavirus pandemic on Thursday, but EW stock popped on a strong first-quarter showing.
Edwards Lifesciences Corp. announced Thursday that sales and profit for the first quarter came in higher than expectations despite COVID-19, sending shares higher even while detailing the financial hit the pandemic will have on its finances. The medical-device company focused on heart procedures reported first-quarter profit of $310.6 million, or $1.47 a share, on sales of $1.13 billion, up from $993 million a year ago. After adjusting for litigation expenses and other costs, the company reported earnings of $1.51 a share, up from $1.32 a share a year ago. Analysts on average expected adjusted earnings of $1.32 a share on sales of $1.08 billion, according to FactSet. Edwards also revealed that it now expects full-year sales of $4 billion to $4.5 billion, after previously guiding for 2020 revenue of $4.6 billion to $5 billion. Earnings are now expected to be $4.75 to $5.25 a share, down from previous guidance of $6.15 to $6.40 a share. "The company assumes the impact of COVID-19 on sales will be most severe in the second quarter, followed by a gradual recovery in the third quarter, and a fourth quarter that better resembles its original expectations for sales," the company disclosed in its announcement. The stock increased more than 3% in after-hours trading following the announcement, after closing the regular session with a 2.1% gain at $221.04.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2020.
NEW YORK, NY / ACCESSWIRE / April 23, 2020 / Edwards Lifesciences Corp. (NYSE:EW) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 23, 2020 at 5:00 ...